Trimetazidine has an antihypoxic effect.
Directly affecting the cardiomyocytes and neurons of the brain, it optimizes their metabolism and function. The cytoprotective effect is caused by an increase in the energy potential, activation of oxidative decarboxylation and rationalization of oxygen consumption (enhancement of aerobic glycolysis and blockade of fatty acid oxidation). Supports contractility of the myocardium, prevents a decrease in the intracellular content of alenosine triphosphate and phosphocreatine.In conditions of acidosis normalizes the functioning of membrane ion channels, prevents the accumulation of calcium and sodium ions in cardiomyocytes, normalizes the intracellular content of potassium ions.
Reduces intracellular acidosis and increased phosphate content, due to myocardial ischemia and reperfusion. It interferes with the damaging effect of free radicals, preserves the integrity of cell membranes, prevents the activation of neutrophils in the ischemic zone, prolongs the duration of the electrical potential, reduces the yield of creatine phosphokinase from cells and the severity of ischemic myocardial damage. With angina reduces the frequency of attacks, after 2 weeks of treatment, tolerance to physical activity increases, blood pressure drops decrease. Reduces dizziness and tinnitus. In vascular pathology, the eye improves the functional activity of the retina.